Workflow
MaxCyte (MXCT) Investor Presentation - Slideshow
MaxCyteMaxCyte(US:MXCT)2022-05-10 15:35

Company Overview - MaxCyte is a leading provider of cell-engineering platform technologies, driving the next generation of cell-based therapies[8] - The company's technology enables the delivery of almost any molecule into almost any cell type[9] - MaxCyte has over 500 platforms in place[9] - The company has 16 Strategic Platform Licenses (SPLs), which include over $1.25 billion in potential pre-commercial milestone payments[10] Financial Performance - MaxCyte experienced approximately 23% 5-year CAGR of organic revenue growth from 2016 to 2021[9] - The company's gross margins are approximately 89%[9] - Total revenue in Q1 2022 was $11.6 million, representing 78% growth compared to Q1 2021[64] - SPL Program-related revenue in Q1 2022 was $2.0 million[64] - The company's core business revenue grew 48% in Q1 2022 compared to the same period in 2021[64] - Total cash, cash equivalents, and short-term investments were $246.3 million as of March 31, 2022[60] Market and Growth Opportunities - The total amount of 2021 global financings for cell and gene therapy companies was $23.1 billion, a 16% increase year-over-year[24] - The company expects core revenue growth of at least 25% compared to 2021 core revenue in 2022[65] - MaxCyte anticipates SPL milestone revenue of approximately $4 million in 2022[65]